La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Tianda Pharmaceuticals Crescita futura

Future criteri di controllo 0/6

Al momento non disponiamo di una copertura analitica sufficiente per prevedere la crescita e il fatturato di Tianda Pharmaceuticals.

Informazioni chiave

n/a

Tasso di crescita degli utili

n/a

Tasso di crescita dell'EPS

Pharmaceuticals crescita degli utili	12.9%
Tasso di crescita dei ricavi	n/a
Rendimento futuro del capitale proprio	n/a
Copertura analitica	None
Ultimo aggiornamento	n/a

Aggiornamenti recenti sulla crescita futura

Recent updates

Tianda Pharmaceuticals Limited (HKG:455) Investors Are Less Pessimistic Than Expected

Aug 16

Is Tianda Pharmaceuticals (HKG:455) Using Debt In A Risky Way?

Jun 20

There's Reason For Concern Over Tianda Pharmaceuticals Limited's (HKG:455) Massive 26% Price Jump

Mar 27

In questa sezione di solito presentiamo le proiezioni di crescita dei ricavi e degli utili basate sulle stime di consenso degli analisti professionisti per aiutare gli investitori a capire la capacità della società di generare profitti. Tuttavia, poiché Tianda Pharmaceuticals non ha fornito dati sufficienti sul passato e non ha previsioni degli analisti, i suoi utili futuri non possono essere calcolati in modo affidabile estrapolando i dati passati o utilizzando le previsioni degli analisti.

Si tratta di una situazione piuttosto rara, dato che il 97% delle società coperte da SimplyWall St dispone di dati finanziari passati.

Previsioni di crescita degli utili e dei ricavi

SEHK:455 - Stime future degli analisti e dati finanziari passati (HKD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2023	532	-24	-116	-50	N/A
12/31/2022	547	-55	69	102	N/A
9/30/2022	523	-18	-61	-11	N/A
6/30/2022	517	-19	-62	-9	N/A
3/31/2022	510	-20	-62	-8	N/A
12/31/2021	517	-25	-107	-24	N/A
9/30/2021	523	-30	-151	-39	N/A
6/30/2021	499	-28	-168	-39	N/A
3/31/2021	474	-27	-184	-38	N/A
12/31/2020	445	-21	-162	-25	N/A
9/30/2020	417	-15	-140	-13	N/A
6/30/2020	454	-6	-131	-16	N/A
3/31/2020	491	3	-122	-20	N/A
12/31/2019	507	3	-108	-26	N/A
9/30/2019	523	3	-94	-32	N/A
6/30/2019	525	3	-54	-7	N/A
3/31/2019	527	3	-14	19	N/A
12/31/2018	514	6	7	30	N/A
9/30/2018	501	10	29	40	N/A
6/30/2018	431	10	37	47	N/A
3/31/2018	362	10	45	54	N/A
12/31/2017	295	7	54	61	N/A
9/30/2017	228	4	N/A	68	N/A
6/30/2017	212	8	N/A	54	N/A
3/31/2017	196	12	N/A	41	N/A
12/31/2016	190	14	N/A	22	N/A
9/30/2016	184	15	N/A	3	N/A
6/30/2016	188	11	N/A	8	N/A
3/31/2016	193	7	N/A	13	N/A
12/31/2015	184	0	N/A	14	N/A
9/30/2015	175	-6	N/A	14	N/A
6/30/2015	157	-12	N/A	-1	N/A
3/31/2015	139	-18	N/A	-16	N/A
12/31/2014	164	-10	N/A	-3	N/A
9/30/2014	189	-3	N/A	9	N/A
6/30/2014	218	10	N/A	34	N/A
3/31/2014	247	22	N/A	58	N/A
12/31/2013	242	26	N/A	N/A	N/A
9/30/2013	237	29	N/A	67	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Dati insufficienti per determinare se la crescita degli utili prevista 455 è superiore al tasso di risparmio ( 2.3% ).

Guadagni vs Mercato: Dati insufficienti per determinare se si prevede che gli utili di 455 cresceranno più velocemente del mercato Hong Kong

Guadagni ad alta crescita: Dati insufficienti per determinare se si prevede che gli utili di 455 cresceranno in modo significativo nei prossimi 3 anni.

Ricavi vs Mercato: Dati insufficienti per determinare se si prevede che i ricavi di 455 cresceranno più rapidamente del mercato Hong Kong.

Ricavi ad alta crescita: Dati insufficienti per determinare se si prevede che i ricavi di 455 cresceranno più rapidamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di 455 è previsto essere elevato tra 3 anni

Tianda Pharmaceuticals Crescita futura

Future criteri di controllo 0/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Tianda Pharmaceuticals Limited Provides Unaudited Consolidated Earnings Guidance for the Six-Month Period from 1 January 2024 to 30 June 2024

Tianda Pharmaceuticals Limited Provides Consolidated Earnings Guidance for the Interim Period Ended June 30, 2023

Tianda Pharmaceuticals Limited Provides Consolidated Earnings Guidance for the Year Ended 31 March 2021

Recent updates

New minor risk - Share price stability

Tianda Pharmaceuticals Limited Provides Unaudited Consolidated Earnings Guidance for the Six-Month Period from 1 January 2024 to 30 June 2024

Tianda Pharmaceuticals Limited (HKG:455) Investors Are Less Pessimistic Than Expected

Tianda Pharmaceuticals Limited to Report First Half, 2024 Results on Aug 28, 2024

Is Tianda Pharmaceuticals (HKG:455) Using Debt In A Risky Way?

Tianda Pharmaceutical Technology (Zhuhai) Co., Ltd. Receives Drug Registration Approval of Ibuprofen Suspension

Tianda Pharmaceuticals Limited Approves Final Dividend

Now 24% overvalued after recent price rise

Tianda Pharmaceuticals Limited, Annual General Meeting, Jun 07, 2024

Now 21% overvalued after recent price rise

There's Reason For Concern Over Tianda Pharmaceuticals Limited's (HKG:455) Massive 26% Price Jump

New major risk - Revenue and earnings growth

Tianda Pharmaceuticals Limited Proposes Final Dividend for the Year Ended 31 December 2023

Tianda Pharmaceuticals Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

New minor risk - Share price stability

Now 26% undervalued

Estimating The Fair Value Of Tianda Pharmaceuticals Limited (HKG:455)

Now 29% undervalued

Tianda Pharmaceuticals Limited Announces Executive Changes, Effective 29 August 2023

Tianda Pharmaceuticals Limited Provides Consolidated Earnings Guidance for the Interim Period Ended June 30, 2023

Tianda Pharmaceuticals Limited to Report First Half, 2023 Results on Aug 28, 2023

Now 28% undervalued

Tianda Pharmaceuticals Limited (SEHK:455) entered into an equity transfer agreement to acquire 45% stake in Yunnan Mengsheng Pharmaceutical Co., Ltd from Yunnan Linuo Biotechnology Co., Ltd. for HKD 23.5 million.

Tianda Pharmaceuticals Limited Announces Board Changes

Now 25% undervalued after recent price drop

Is Tianda Pharmaceuticals (HKG:455) Using Debt Sensibly?

Tianda Pharmaceuticals Limited, Annual General Meeting, Jun 27, 2023

Full year 2022 earnings released: HK$0.025 loss per share (vs HK$0.011 loss in FY 2021)

Executive Chairman & MD recently bought HK$2.7m worth of stock

Executive Chairman & MD recently bought HK$448k worth of stock

Executive Chairman & MD recently bought HK$52k worth of stock

Tianda Pharmaceuticals (HKG:455) Has Debt But No Earnings; Should You Worry?

First half 2023 earnings released: HK$0.008 loss per share (vs HK$0.008 loss in 1H 2022)

Tianda Pharmaceuticals Limited to Report First Half, 2023 Results on Nov 25, 2022

Less than half of directors are independent

Executive Chairman & MD recently bought HK$129k worth of stock

Tianda Pharmaceuticals Limited Declares Final Dividend

Tianda Pharmaceuticals Limited, Annual General Meeting, Aug 25, 2022

Tianda Pharmaceuticals Limited Proposes Final Dividend for the Year Ended March 31, 2022, Payable on September 08, 2022

Full year 2022 earnings released

Tianda Pharmaceuticals Limited Proposes Special Dividend for the Year Ended 31 March 2022

Tianda Pharmaceuticals Limited to Report Fiscal Year 2022 Results on Jun 29, 2022

Less than half of directors are independent

Does Tianda Pharmaceuticals (HKG:455) Have A Healthy Balance Sheet?

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Non-Executive Director Lee George Lam has left the company

Does Tianda Pharmaceuticals (HKG:455) Have A Healthy Balance Sheet?

Full year 2021 earnings released: HK$0.013 loss per share (vs HK$0.001 profit in FY 2020)

Full year 2021 earnings released: HK$0.013 loss per share (vs HK$0.001 profit in FY 2020)

Tianda Pharmaceuticals Limited Provides Consolidated Earnings Guidance for the Year Ended 31 March 2021

First half 2021 earnings released: HK$0.007 loss per share

Is Tianda Pharmaceuticals (HKG:455) Using Too Much Debt?

First half 2021 earnings released: HK$0.007 loss per share

Tianda Pharmaceuticals Limited to Report First Half, 2021 Results on Nov 27, 2020

Previsioni di crescita degli utili e dei ricavi

Previsioni di crescita futura degli analisti

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

Scoprire le aziende in crescita